Companies Investors People

Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

Contact
Request a Demo
Request Data Updates
Add a Company

Research

Companies
Investors
People

aVenture

Download App
Pricing

Resources

Documentation
Use Cases
CLI
MCP
Feature Requests
Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading

Violet Therapeutics›

Library

Violet Therapeutics

Preclinical biotech developing first-in-class CNS therapies via the CONNECT platform, targeting EphB3 for neurodegenerative diseases.

Norwalk, CT, US🇺🇸

Founded

Loading

Violet Therapeutics Website, Blog & Press Pages - aVenture

Violet Therapeutics - Library

violettx.comCrawled Sep 28, 2026

Topics

Publication type

Search the library

Content origin

Row density

Team

1 page

Team/team
Meet Violet Therapeutics’ experienced biotech leadership team driving innovation in neurodegenerative disease research and therapeutic development.

Homepage

1 page

Homepage/
Violet Therapeutics is advancing EphB3 inhibitors to reduce neuroinflammation and help treat neurodegenerative diseases like Alzheimer’s and Parkinson’s.

Coverage

2 items

Violet Therapeutics Announces .75M Seed Extension for Neurodegenerative Drug Developmentsvhealthinvestors.com/news/violet-therapeutics-announces-4-75m-seed-extension-for-neurodegenerative-drug-development
Violet Therapeutics raises a .75 million seed extension to advance its lead program targeting EphB3 for neurodegenerative diseases. Lifespan Vision Ventures leads the round, with participation from the Dementia Discovery Fund, UTEC, Ono Venture Investment, and Mass General Brigham Ventures. The company’s CONNECT platform maps disease-relevant cell-to-cell signaling interactions to discover novel CNS targets.
May 2026 · SV Health InvestorsNews article
Violet Therapeutics Raises .75M Seed Extensionprnewswire.com/news-releases/lifespan-vision-ventures-leads-violet-therapeutics-4-75m-seed-extension-financing-302774963.html
Violet Therapeutics raises a seed extension financing round led by Lifespan Vision Ventures, with participation from the Dementia Discovery Fund, UTEC, Ono Venture Investment, and Mass General Brigham Ventures. The company will use the proceeds to advance its lead small molecule program targeting EphB3 for neurodegenerative diseases.
May 2026 · PR NewswireNews article